Quick Summary
- Theriva Biologics (TOVX) shares climbed 63% following presentation of VIRAGE Phase 2b trial results
- Combination therapy of VCN-01 with standard chemotherapy demonstrated extended overall survival compared to chemotherapy alone in metastatic pancreatic cancer
- Positive outcomes observed across multiple patient subgroups, including those with liver metastases
- Theriva secured FDA and EMA agreement on Phase 3 pivotal trial design
- Current market capitalization stands at $11.7M with shares trading at $0.25, consistent with early-stage clinical development risk
Theriva Biologics unveiled fresh clinical data from its VIRAGE Phase 2b study during the American Association for Cancer Research (AACR) Annual Meeting held in San Diego on April 20, 2026.
Dr. Manuel Hidalgo from NYU Langone Health’s Perlmutter Cancer Center presented the poster session.
The clinical study evaluated VCN-01 in combination with gemcitabine and nab-paclitaxel versus chemotherapy alone among patients with newly diagnosed metastatic pancreatic cancer.
Findings demonstrated that participants receiving VCN-01 alongside chemotherapy achieved superior overall survival and progression-free survival compared to those receiving chemotherapy alone.
Responses observed in the VCN-01 cohort emerged later, demonstrated greater magnitude, and exhibited longer duration — characteristics the company interprets as evidence of an immune-mediated mechanism of action.
Survival advantages remained broadly consistent across various patient subgroups. This consistency extended to patients with liver metastases, a population known for treatment challenges.
Participants who received a second VCN-01 dose demonstrated enhanced benefit, supporting the rationale for extended dosing schedules according to the company.
Regulatory Agreement on Phase 3 Design
Theriva announced successful alignment with both the FDA and the European Medicines Agency regarding the structure of a pivotal Phase 3 trial.
The planned Phase 3 study would assess multiple doses of VCN-01 combined with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer patients.
Theriva also outlined plans for an additional smaller study examining whether increased frequency or extended duration of VCN-01 administration could further enhance patient outcomes.
VCN-01 represents a systemically delivered oncolytic adenovirus. The therapy replicates within tumor cells and degrades tumor stroma, potentially enhancing access for co-administered treatments.
To this point, 142 patients have received the treatment across clinical trials spanning multiple cancer types.
Market Response and Company Overview
TOVX shares surged 63% following the announcement, while the company maintains a market capitalization of $11.7 million at a share price of $0.25.
This valuation corresponds with the inherent risks associated with a clinical-stage biotechnology company operating without revenue and continuing cash expenditure.
Analyst Perspective
The latest analyst assessment on TOVX stands at Buy, featuring a price target of $1.00. Analyst price targets span from $1 to $4.
A notable development: Theriva recently failed to achieve quorum for a Special Meeting of Stockholders intended to approve a warrant exercise proposal. The company intends to reschedule this meeting.
Pancreatic ductal adenocarcinoma accounts for over 90% of all pancreatic tumors, with 50–60% of patients presenting with distant metastases at initial diagnosis.
The AACR presentation occurred on April 20 from 2:00–5:00 PM PDT at the San Diego Convention Center.
